C07C 259/04
Without replacement of the other oxygen atom of the carboxyl group
Official title: without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
C07C259/04 (Without replacement of the other oxygen atom of the carboxyl group) appears on 975 US grants and 833 published applications in this corpus.
Search patents in C07C- Granted patents
- 975
- Published applications
- 833
- Assignees
- 533
- Inventors
- 2,661
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 7 | 0 |
| 1991 | 20 | 0 |
| 1992 | 21 | 0 |
| 1993 | 21 | 0 |
| 1994 | 20 | 0 |
| 1995 | 22 | 0 |
| 1996 | 20 | 0 |
| 1997 | 46 | 0 |
| 1998 | 41 | 0 |
| 1999 | 50 | 0 |
| 2000 | 42 | 0 |
| 2001 | 36 | 11 |
| 2002 | 40 | 32 |
| 2003 | 34 | 36 |
| 2004 | 25 | 50 |
| 2005 | 24 | 40 |
| 2006 | 26 | 25 |
| 2007 | 12 | 41 |
| 2008 | 24 | 37 |
| 2009 | 22 | 41 |
| 2010 | 20 | 32 |
| 2011 | 29 | 39 |
| 2012 | 31 | 27 |
| 2013 | 27 | 24 |
| 2014 | 33 | 51 |
| 2015 | 25 | 32 |
| 2016 | 32 | 40 |
| 2017 | 36 | 43 |
| 2018 | 26 | 27 |
| 2019 | 20 | 37 |
| 2020 | 28 | 26 |
| 2021 | 22 | 25 |
| 2022 | 19 | 33 |
| 2023 | 15 | 25 |
| 2024 | 17 | 26 |
| 2025 | 21 | 14 |
| 2026 | 12 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- N-formylhydroxylamines as neprilysin (NEP) inhibitors, in particular as mixed aminopeptidase N (APN) and neprilysin (NEP) inhibitors6 Oct 2026US 12,753,149 B2Kos Therapeutics, Inc.
- Reagents and methods for aliphatic carbon-hydrogen bond functionalization1 Sep 2026US 12,723,112 B2The University of North Carolina at Chapel Hill
- Ferroptosis inhibitors—diarylamine para-acetamides25 Aug 2026US 12,715,855 B2Sironax Ltd.
- Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications9 Jun 2026US 12,649,712 B2NucMito Pharmaceuticals Co. Ltd.
- Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors26 May 2026US 12,637,413 B2Autobahn Therapeutics, Inc.
- Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications1 Oct 2026US 2026/0297012 A1NucMito Pharmaceuticals Co. Ltd.
- System for producing remote sensing data from near earth orbit3 Sep 2026US 2026/0257991 A1Skeyeon, Inc.
- New compounds for treating streptococcus infections6 Aug 2026US 2026/0225998 A1AB2 Therapeutics, S. L.
- Processes and intermediates for synthesis of adagrasib6 Aug 2026US 2026/0226045 A1Mirati Therapeutics, Inc.
- Substituted Hydroxystilbene Compounds and Derivatives, Synthesis and Uses Thereof23 Jul 2026US 2026/0209152 A1Kynan Duke IP, LLC
Most cited
By later US patents
- Deacetylase inhibitors168US 6,552,065 B2Novartis AG · 2003
- Compositions for oral delivery of active agents159US 5,650,386 AEmisphere Technologies, Inc. · 1997
- Bicyclic naphthalenic derivatives, a process for preparing the same and human or veterinary medicines and cosmetic compositions containing said derivatives142US 4,826,969 ACentre International de Recherches Dermatologiques (C.I.R.D.) · 1989
- Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method125US 5,760,246 A1998
- Compounds and compositions for delivering active agents125US 5,866,536 AEmisphere Technologies, Inc. · 1999